MIAMI, FL / ACCESSWIRE / February 14 , 2017 / Biotech Products Services and Research, Inc. (OTC PINK: BPSR) ("Company") today announced that its wholly-owned subsidiary, Anu Life Sciences Inc. ("Anu"), has recently received satisfactory validation for its first production batch of amniotic allograft biological product ("New Amnio Product") and has commenced shipping the New Amnio Product to customers. The New Amnio Product is being sold through Anu's designated distributor and affiliate, General Surgical Inc. ("General Surgical"), under the name "Regen Anu Rheo." The Company expects to increase production of the New Amnio Product in quantities to ensure there is satisfactory inventory to meet anticipated demand.
The commencement of Regen Anu Rheo shipments follows the Company's January 12, 2017 announcement that it had successfully completed trial production runs of Regen Anu Rheo and was only awaiting satisfactory confirmation of test results before commencing distribution.
Regen Anu Rheo is the first of several amniotic-based biologics products that the Company intends to develop, manufacture and supply to the health care industry, specifically health care providers including doctors, clinics and hospitals ("Providers").
Mr. Albert Mitrani, the Company's Chief Executive Officer commented, "We are excited to have successfully developed and produced the first of many of our planned newly developed innovative biologic tissue products. We believe that our proprietary protocols for the processing of amniotic tissue are superior to those processes used in existing amniotic tissue derived products produced by our competitors."
About Biotech Products Services and Research, Inc.
Biotech Products Services and Research, Inc. and its subsidiaries ("Company") is a supplier of products and services used in the growing health care field of regenerative medicine.
The Company's strategy is to be a leading supplier of newly designed advanced biologically processed cellular and tissue based products and services used in the growing health care field of regenerative medicine.
CAUTIONARY COMMENT REGARDING FORWARD-LOOKING STATEMENTS
The foregoing contains "forward-looking statements" within the meaning of the Private Securities Litigation Reform Act of 1995. We intend for these forward-looking statements to be covered by the safe harbor provisions of the federal securities laws relating to forward-looking statements. This release contains forward-looking statements that reflect Biotech Products Services & Research, Inc., and its subsidiaries, plans and expectations. In this press release and related comments by Company management, words like "expect," "anticipate," "estimate," "goal" and similar expressions are used to identify forward-looking statements, representing management's current judgment and expectations about possible future events.
Management believes these forward-looking statements and the judgments upon which they are based to be reasonable, but they are not guarantees of future performance and involve numerous known and unknown risks, uncertainties and other factors that may cause the Company's actual results, performance, achievements or financial position to be materially different from any expressed or implied by these forward-looking statements. Important factors that could cause actual results to differ materially from the forward-looking statements are set forth in our Form 10-K and other filings with the SEC. Other information can be obtained at www.bpsrhealth.com. The contents of the Company's website are not incorporated by reference in this Press Release.
SOURCE: Biotech Products Services and Research Inc.